

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.webje.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/586,345	07/14/2006	Johannes Reinmuller	WEICKM-0061	2694	
23599 7590 10/28/2010 MILLEN, WHITE, ZELANO & BRANIGAN, P.C.			EXAM	EXAMINER	
2200 CLARENDON BLVD.			GOON, SCARLETT Y		
SUITE 1400 ARLINGTON, VA 22201		ART UNIT	PAPER NUMBER		
	,		1623		
			NOTIFICATION DATE	DELIVERY MODE	
			10/28/2010	EI ECTRONIC	

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

docketing@mwzb.com

	Application No.	Applicant(s)			
Examiner-Initiated Interview Summary	10/586,345	REINMULLER ET AL.			
Examiner-initiated interview Summary	Examiner	Art Unit			
	SCARLETT GOON	1623			
All Participants: Status of Application: pending					
(1) <u>SCARLETT GOON</u> .	(3)				
(2) Mr. Csaba Henter, Applicants' Atty.	(4)				
Date of Interview: 15 October 2010	Time: <u>5:12 pm</u>				
Type of Interview:	ant's representative)				
Part I.					
Rejection(s) discussed: none					
Claims discussed: see below					
Prior art documents discussed: see below					
Part II. SUBSTANCE OF INTERVIEW DESCRIBING THE GENE See Continuation Sheet	RAL NATURE OF WHAT WAS	S DISCUSSED:			
Part III.					
<ul> <li>It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.</li> <li>It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.</li> </ul>					
/SCARLETT GOON/ Examiner, Art Unit 1623	Applicant/Applicant's Representat	ive Signature – if appropriate)			

Application No. 10/586,345

Continuation of Substance of Interview including description of the general nature of what was discussed: Mr. Henter was contacted to discuss potential allowable subject matter. The Examiner indicated that the claims would be allowable if Applicants amended the claims to limit the scope of inflammatory skin or mucous membrane diseases to only those related to warts, specifically, those recited in the claims as a vital skin disease which leads to wart formation, verruca vulgaris, and Condylomata accuminata. The Examiner further indicated that the withdrawn claims woulld also be rejoined and allowable if they depended from the allowed subject matter. Mr. Henter indicated he would contact Applicants and discuss the proposed amendments with them.